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Conclusions: Sng and Sep plans were very similar from the 
dosimetric (D98, D95, D50, D02) and volumetric (V40) point 
of view. However, in terms of dose delivery (Time, MU), 
differences were remarkable. This may ecologically 
profitable and save patient times. These differences were 
unfluctuating, even if the ROV were changed broadly in the 
clinical situation. 
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Purpose/Objective: To report toxicity considering overall 
treatment time of intensity Modulated Arc Therapy (IMAT) 
with simultaneous integrated boost (SIB) for patients with 
intermediate or high-risk prostate cancer.  
Materials and Methods: One hundred forty two consecutive 
patients, diagnosed with intermediate or high risk prostate 
cancer, were treated definitively between September 2011 
and May 2014. Androgen suppression was administered 
considering disease risk factors. The IMAT plans were 
designed to deliver 70.8 Gy in 30 fractions (2.36 Gy/fraction) 
while delivering simultaneously to the prostate plus margin 
60 Gy (2Gy/fraction).Univariate and multivariate analysis 
with logistic regression were performed looking for relations 
among patient characteristics and toxicity. CTCAE v3.0 
morbidity scores were used to assess acute and late 
toxicities. Outcome, measurements: toxicity and biochemical 
response were assessed prospectively. 
Results: Median age of those patients was 72 years old (from 
58 to 81). Pathologically centralized Gleason score was 7 for 
81.7 % of patients. Mean PSA value was 9.6 ng/ml (from 2 to 
36ng/ml). Forty one percent of patients were classified as 
T1-T2a, 37.5% as T2b-c and 21.5% as T3. Median IPPS was 5 (0 
to15). The median follow-up period was 14.8 months. All 
patients received the prescribed dose in 30 fractions 
delivered between 36 to 57days. Median radiation overall 
treatment time (OTT) was 47 days. Seventy-five percent of 
patients received a course of hormone deprivation for 6 
months at least. One biochemical relapse was observed in 
this cohort of patients. Five patients died during the follow-
up period without cancer relapse or toxicity. Acute genito-
urinary toxicity was observed in 81% of patients with maximal 
score of 2 in 40.9% of patients. Rectal acute toxicity grade 2 
with mucosal discharge was present in 17.6%. Presence of any 
acute rectal toxicity risk is increased by 2.3 fold in the 
shorter OTT. Late rectal toxicity Grade 3 was seen in one 
patient and 5 more patients showed grade 2 score. Chronic 
urinary toxicity grades 1-2 were observed in 27.5% of 
patients, but only two patients with grade 2. Absence of 
acute toxicities decreased the risk for chronic rectal toxicity 
by 0.2 and urinary by 0.09. Neither, hormonal deprivation nor 
fiducial markers for IGRT showed any impact on toxicity. 
Presence of any acute rectal toxicity risk is increased by 2.3 
fold in the shorter OTT. Initial IPSS increased 1.2 fold the risk 
to present any grade of late the urinary toxicity.  
Conclusions: IMAT with SIB to the prostate was well 
tolerated in this series, with acceptable rates of acute and 
early late toxicity. Shorter OTT seems to increase the risk of 
acute rectal toxicity whereas initial IPSS increased the risk of 
late urinary toxicity. The absence of both acute rectal and 
urinary toxicities decreased the risk of chronic toxicities. 
Additional follow-up is necessary to fully define the long-
term toxicity.  
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Purpose/Objective: We initiated a correlative analysis of 
urinary toxicity (UT) and radiation-induced lymphopenia to 
test the hypothesis that patients (pts) experiencing more 
severe lymphopenia may be at higher risk for UT, owing to 
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suboptimal repair of RT-induced damages to local blood cells 
circulating in the pelvis during irradiation (RT) and reduced 
pelvic hematopoiesis. 
Materials and Methods: In 2012 a prospective, observational, 
study evaluating hematologic and urinary toxicity after 
whole-pelvis radiotherapy (WPRT) was activated. For the 
study purposes, the International Prostate Symptoms Score 
questionnaire (IPSSq) has to be filled by pts and a blood 
sample has to be obtained at baseline, at RT mid-point and 
end, and after 3, 6, 12, 18, 24, 30 and 36 months. RT was 
delivered with static-field IMRT, Tomotherapy and VMAT in 
17, 23 and 34 pts, respectively, at conventional fractionation 
(CF, 1.8-2 Gy) in 24 and with moderate hypofractionation 
(HYPO, median 2.35 Gy/fraction) in 50. WPRT was delivered 
at up to 50.4 Gy/28 fractions in CF and at 52.50 Gy/30 
fractions in HYPO. The median variation (delta, Δ) of 
absolute lymphocyte count at given time over baseline (Δ 
ALC) was calculated. 
Results: For 74 pts both baseline and one year IPSSq were 
collected, for 69 blood samples were taken at baseline and 
RT midpoint and end, for 66, 67 and 71 pts also at 3, 6 and 12 
months, respectively. The median ΔALC at RT mid-point and 
end, and at 3, 6 and 12 months after WPRT completion was 
35%, 30%, 45%, 50% and 54%, respectively. A borderline 
association between ΔALCs and ΔIPSS at 12 months was found 
(Mann-Whitney test: p-values 0.056-0.09). Unexpectedly, by 
setting the event for logistic regression analysis as the 75th 
percentile of 12 months ΔIPSS (ΔIPSS12, ≥4), the mean ΔALC 
was always higher in pts with late UT when compared to pts 
without UT (Figure 1). Variables with a p-value <0.10 at 
univariate analysis (i.e. time from prostatectomy to RT, 
volume of lymph-nodal irradiated area and ΔALC at RT mid-
point and 6 months), were entered into a multivariable Cox 
model which confirmed an independent role for ΔALC at 6 




Conclusions: These results indicate that pts with reduced RT-
induced lymphopenia are at higher risk for UT when 
compared to more lymphopenic patients. Given the notion 
that RT favours leukocyte extravasation (Vianello et al. Br J 
Hemat 2013), we postulate that late UT may be caused, at 
least in part, by tissue-infiltrating leukocytes able to 
propagate local inflammation and more pronounced fibrotic 
processes in the late regenerative phase, one of the possible 
main causes for the onset of late UT following RT.  
These data provide rationale for addressing changes of 
inflammatory markers during/after RT and support the use of 
ΔALC as predictive of UT. 
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Purpose/Objective: To assess the effects of verification 
imaging protocol on the actual doses delivered to the target 
volume and organs at risk during a course of image-guided 
radiotherapy (IGRT) for prostate cancer. 
Materials and Methods: 844 cone-beam CT (CBCT) 
verification images from 20 patients undergoing radical 
prostate radiotherapy were analysed. All patients received a 
dose of 74 Gy in 37 fractions using 7-field intensity-
modulated radiotherapy (IMRT). During treatment, patients 
had daily online CBCT soft tissue match verification using the 
Elekta XVI system. Early toxicity was assessed using the RTOG 
acute radiation morbidity scale. All CBCT images were 
imported into the Pinnacle treatment planning system. 
Target volume and organs at risk were contoured manually on 
each CBCT image. A 7 mm margin in all directions was used 
around the clinical target volume (CTV) to obtain the 
planning target volume (PTV). Soft tissue match shifts were 
separately applied to each CBCT image. The CBCT contours 
were superimposed on the planning CT scan for dose-volume 
analysis. Dose-volume parameters were assessed for the PTV, 
CTV, rectum and bladder. The same contours were used for 
comparison of a daily online schedule with a protocol of day 
1-3 followed by weekly imaging. A further comparison was 
carried out between online and offline weekly verification 
schedules. Paired t test and Wilcoxon signed rank test were 
used to compare parametric and non-parametric dosimetric 
statistics. 
Results: 90% of patients had improvement in prostate target 
coverage with daily online imaging in comparison to weekly 
online imaging, with statistically significant benefits in 
dosimetric parameters assessed (Table 1). Daily online 
imaging was the best verification protocol, with a median of 
37 fractions (out of 37) achieving CTV coverage with daily 
imaging compared with 33 and 34 fractions respectively with 
weekly offline and weekly online protocols (Fig. 1). There 
were low levels of acute toxicity in the patient population 
when daily imaging was used. On dosimetric analysis, 80% of 
patients had a reduction in rectal dose with the daily imaging 
protocol. On average, there was a 1.13 Gy reduction in mean 
rectal dose, which would mitigate the concomitant dose to 
